StockpollyBeta
Get App
Popularity #3,573
DTIL · NASDAQ · Biotechnology

Precision BioSciences (DTIL)

Develops ARCUS-based in vivo gene-editing therapies.

$7.02
vs last close+0.52 (+8.00%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue13718501100034110
Cost of revenue200000000000
Gross profit11718501100034110
232222262225222221222019
Research & development151313171316141313141312
9989910997777
General & administrative0989910997777
Operating income−12−15−424−21−25−22−22−2113−9−19
01139572−2−17−9−13
Interest income222221111111
Interest expense111100000000
Other non-operating income−1−2−13−9−5−7−211−7913
Income before tax−12−13933−16−18−21−24−2219−18−33
Net income from continuing operations−12−13933−16−18−21−24−2219−18−33
Discontinued operations−4−30000000000
Other adjustments000000000100
Net income−17−16933−16−18−21−24−2220−18−33
EPS, basic−$2.10−$3.66$1.70$4.70−$2.25−$2.51−$2.30−$2.13−$1.84$1.06−$0.75−$1.26
EPS, diluted−$2.10−$3.66$1.70$4.67−$2.25−$2.50−$2.29−$2.13−$1.84$1.05−$0.75−$1.26
Weighted average shares, basic44577791112192526
Weighted average shares, diluted44577791112192526
EBITDA−9−111135−15−17−20−22−2120−17−32
Depreciation & amortization221111111110
EBIT−12−13933−16−17−20−23−2120−18−32